NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$13.10 -0.85 (-6.09 %)
(As of 05/25/2018 08:35 AM ET)
Previous Close$13.95
Today's Range$12.20 - $13.40
52-Week Range$6.10 - $18.00
Volume1.56 million shs
Average Volume268,835 shs
Market Capitalization$147.04 million
P/E Ratio-2.70
Dividend YieldN/A
Beta1.6

About Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals logoEiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-279-9845

Debt

Debt-to-Equity Ratio0.81
Current Ratio4.51
Quick Ratio4.51

Price-To-Earnings

Trailing P/E Ratio-2.70
Forward P/E Ratio-3.61
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.40 per share
Price / Book9.36

Profitability

EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-227.27%
Return on Assets-105.48%

Miscellaneous

Employees16
Outstanding Shares10,540,000

Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR) issued its quarterly earnings results on Friday, May, 11th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.96) by $0.12. View Eiger Biopharmaceuticals' Earnings History.

What price target have analysts set for EIGR?

7 analysts have issued 1 year target prices for Eiger Biopharmaceuticals' shares. Their forecasts range from $24.00 to $39.00. On average, they anticipate Eiger Biopharmaceuticals' stock price to reach $31.4286 in the next year. View Analyst Ratings for Eiger Biopharmaceuticals.

Who are some of Eiger Biopharmaceuticals' key competitors?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the folowing people:
  • Mr. David A. Cory R.Ph, MBA, Pres, CEO, Director & Bus. Founder (Age 54)
  • Dr. Jeffrey S. Glenn M.D., Ph.D., Founder, Scientific Advisor & Director (Age 55)
  • Dr. Joanne M. J. Quan M.D., Chief Medical Officer (Age 54)
  • Mr. James P. Shaffer MBA, Chief Bus. Officer (Age 51)
  • Mr. James A. Welch MBA, Chief Financial Officer (Age 60)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

News coverage about EIGR stock has trended very positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of 0.65 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 48.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Eiger Biopharmaceuticals' major shareholders?

Eiger Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Prosight Management LP (5.04%), Sphera Funds Management LTD. (4.51%), BlackRock Inc. (0.77%), Unterberg Capital LLC (0.76%), Eventide Asset Management LLC (0.60%) and Knott David M (0.59%). Company insiders that own Eiger Biopharmaceuticals stock include James H Welch, James P Shaffer, Jeffrey S Glenn, Joanne Quan and Ventures Fund Vi LP Vivo. View Institutional Ownership Trends for Eiger Biopharmaceuticals.

Which institutional investors are selling Eiger Biopharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Eventide Asset Management LLC, Sphera Funds Management LTD. and Sabby Management LLC. View Insider Buying and Selling for Eiger Biopharmaceuticals.

Which institutional investors are buying Eiger Biopharmaceuticals stock?

EIGR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Knott David M, Unterberg Capital LLC, Wedbush Securities Inc., Northern Trust Corp and DRW Securities LLC. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Insider Buying and Selling for Eiger Biopharmaceuticals.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $13.10.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $147.04 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 350 CAMBRIDGE AVE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-279-9845 or via email at [email protected]


MarketBeat Community Rating for Eiger Biopharmaceuticals (EIGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eiger Biopharmaceuticals (NASDAQ:EIGR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Eiger Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $31.4286, suggesting that the stock has a possible upside of 139.91%. The high price target for EIGR is $39.00 and the low price target for EIGR is $24.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.4286$29.00$29.00$33.00
Price Target Upside: 139.91% upside205.26% upside81.25% upside194.64% upside

Eiger Biopharmaceuticals (NASDAQ:EIGR) Consensus Price Target History

Price Target History for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ:EIGR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Piper Jaffray CompaniesBoost Price TargetOverweight$28.00HighView Rating Details
5/17/2018OppenheimerSet Price TargetBuy$26.00HighView Rating Details
5/17/2018BTIG ResearchBoost Price TargetBuy ➝ Buy$23.00 ➝ $39.00HighView Rating Details
5/17/2018WedbushReiterated RatingOutperform$53.00 ➝ $36.00HighView Rating Details
5/9/2018B. RileyInitiated CoverageBuy ➝ Buy$24.00HighView Rating Details
1/3/2018Ladenburg ThalmannInitiated CoverageBuy ➝ Buy$32.00HighView Rating Details
10/19/2017Roth CapitalInitiated CoverageBuy ➝ Buy$35.00N/AView Rating Details
5/15/2017Jefferies GroupReiterated RatingBuy$28.00 ➝ $27.00MediumView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Eiger Biopharmaceuticals (NASDAQ:EIGR) Earnings History and Estimates Chart

Earnings by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ:EIGR) Earnings Estimates

2018 EPS Consensus Estimate: ($3.75)
2019 EPS Consensus Estimate: ($2.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($1.12)($0.87)($1.03)
Q2 20184($0.98)($0.78)($0.89)
Q3 20184($1.13)($0.69)($0.91)
Q4 20184($1.34)($0.61)($0.92)
Q1 20191($0.74)($0.74)($0.74)
Q2 20191($0.70)($0.70)($0.70)
Q3 20192($0.71)($0.66)($0.69)
Q4 20192($0.73)($0.63)($0.68)

Eiger Biopharmaceuticals (NASDAQ EIGR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2018Q1 2018($0.96)($0.84)ViewN/AView Earnings Details
3/12/2018Q4 2017($1.02)($1.11)ViewN/AView Earnings Details
11/9/2017Q3 2017($1.28)($1.10)ViewN/AView Earnings Details
8/14/2017Q2 2017($1.2840)($1.33)ViewN/AView Earnings Details
5/12/2017Q1 2017($1.35)($1.34)ViewN/AView Earnings Details
3/23/2017Q4 2016($1.3830)($1.53)ViewN/AView Earnings Details
11/8/2016Q3 2016($1.21)($1.49)ViewN/AView Earnings Details
8/10/2016Q2($1.17)($1.87)ViewN/AView Earnings Details
5/16/2016Q1($1.69)($10.42)ViewN/AView Earnings Details
11/9/2015Q3 2015($3.30)($4.05)ViewN/AView Earnings Details
8/11/2015Q2($0.32)($0.69)ViewN/AView Earnings Details
5/14/2015Q1 2015($6.90)($10.64)ViewN/AView Earnings Details
3/31/2015Q414($0.36)($0.49)ViewN/AView Earnings Details
11/12/2014Q3 2014($0.39)($0.40)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.39)($0.38)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.44)($0.58)ViewN/AView Earnings Details
3/31/2014Q4 2013($0.47)($7.96)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Eiger Biopharmaceuticals (NASDAQ:EIGR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 65.92%
Insider Trading History for Eiger Biopharmaceuticals (NASDAQ:EIGR)
Institutional Ownership by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Eiger Biopharmaceuticals (NASDAQ EIGR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Joanne QuanInsiderSell4,000$10.00$40,000.004,000View SEC Filing  
9/1/2017Jeffrey S GlennDirectorBuy15,000$9.53$142,950.0031,355View SEC Filing  
11/18/2016Jeffrey S GlennDirectorBuy15,460$12.74$196,960.4016,355View SEC Filing  
8/18/2016James P ShafferInsiderBuy3,125$15.70$49,062.505,620View SEC Filing  
8/18/2016Ventures Fund Vi L.P. VivoMajor ShareholderBuy187,500$16.00$3,000,000.00View SEC Filing  
6/22/2016James H WelchCFOBuy2,500$19.80$49,500.002,000View SEC Filing  
6/13/2016James P ShafferInsiderBuy1,250$22.17$27,712.501,975View SEC Filing  
5/23/2016James P ShafferInsiderBuy1,245$19.80$24,651.00500View SEC Filing  
4/6/2015Krisztina M ZseboCEOSell47,931$18.20$872,344.20View SEC Filing  
4/2/2015Rebecque J LabaVPSell11,012$17.30$190,507.60View SEC Filing  
3/9/2015Krisztina M ZseboCEOSell47,931$24.80$1,188,688.80View SEC Filing  
3/6/2015Peter HonigDirectorSell9,700$23.74$230,278.00View SEC Filing  
3/6/2015Rebecque J LabaVPSell14,000$23.06$322,840.00View SEC Filing  
3/2/2015Ryan K TakeyaVPSell7,777$18.48$143,718.96View SEC Filing  
2/9/2015Krisztina M ZseboCEOSell47,931$15.86$760,185.66View SEC Filing  
2/6/2015Rebecque J LabaVPSell14,000$16.08$225,120.00View SEC Filing  
2/2/2015Ryan K TakeyaVPSell7,777$16.35$127,153.95View SEC Filing  
1/9/2015Jeffrey J RudyVPSell10,000$18.51$185,100.00View SEC Filing  
1/7/2015Rebecque J LabaVPSell20,000$17.30$346,000.00View SEC Filing  
1/6/2015Krisztina M ZseboCEOSell41,302$17.51$723,198.02View SEC Filing  
1/2/2015Ryan K TakeyaVPSell7,777$19.88$154,606.76View SEC Filing  
12/9/2014Jeffrey J RudyVPSell10,000$15.00$150,000.00View SEC Filing  
12/9/2014Krisztina M ZseboCEOSell41,302$15.00$619,530.00View SEC Filing  
12/5/2014Rebecque J LabaVPSell20,000$12.77$255,400.00View SEC Filing  
12/1/2014Ryan K TakeyaVPSell7,777$12.01$93,401.77View SEC Filing  
2/4/2014Enterprise Partners ManagementMajor ShareholderBuy133,083$8.00$1,064,664.00View SEC Filing  
2/4/2014Fredrik WiklundVPBuy20,000$8.00$160,000.00View SEC Filing  
2/4/2014Todd FoleyDirectorBuy111,608$8.00$892,864.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eiger Biopharmaceuticals (NASDAQ EIGR) News Headlines

Source:
DateHeadline
Eiger BioPharmaceuticals (EIGR) Prices 3.2M Common Stock Offering at $12.50/ShareEiger BioPharmaceuticals (EIGR) Prices 3.2M Common Stock Offering at $12.50/Share
www.streetinsider.com - May 24 at 5:41 PM
BRIEF-Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common StockBRIEF-Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock
www.reuters.com - May 23 at 5:35 PM
Eiger BioPharmaceuticals: Elucidating The Fundamentals Powering A Big WinnerEiger BioPharmaceuticals: Elucidating The Fundamentals Powering A Big Winner
seekingalpha.com - May 23 at 8:18 AM
Wedbush Comments on Eiger Biopharmaceuticals Inc.s Q3 2019 Earnings (EIGR)Wedbush Comments on Eiger Biopharmaceuticals Inc.'s Q3 2019 Earnings (EIGR)
www.americanbankingnews.com - May 21 at 1:44 AM
-$0.83 EPS Expected for Eiger Biopharmaceuticals Inc. (EIGR) This Quarter-$0.83 EPS Expected for Eiger Biopharmaceuticals Inc. (EIGR) This Quarter
www.americanbankingnews.com - May 20 at 9:06 PM
Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66 ...Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66 ...
247wallst.com - May 19 at 5:54 PM
Eiger Biopharmaceuticals (EIGR) Given a $26.00 Price Target by Oppenheimer AnalystsEiger Biopharmaceuticals (EIGR) Given a $26.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 18 at 5:47 PM
Eiger Biopharmaceuticals (EIGR) PT Raised to $28.00Eiger Biopharmaceuticals (EIGR) PT Raised to $28.00
www.americanbankingnews.com - May 18 at 5:07 PM
Reader Inquiry: Is There Further Upside Ahead For Eiger BioPharmaceuticals?Reader Inquiry: Is There Further Upside Ahead For Eiger BioPharmaceuticals?
seekingalpha.com - May 18 at 8:40 AM
Today’s Research Reports on Stocks to Watch: Eiger BioPharmaceuticals and Nektar TherapeuticsToday’s Research Reports on Stocks to Watch: Eiger BioPharmaceuticals and Nektar Therapeutics
finance.yahoo.com - May 18 at 8:40 AM
Q2 2018 Earnings Estimate for Eiger Biopharmaceuticals Inc. Issued By Jefferies Group (EIGR)Q2 2018 Earnings Estimate for Eiger Biopharmaceuticals Inc. Issued By Jefferies Group (EIGR)
www.americanbankingnews.com - May 18 at 7:38 AM
Eiger Biopharmaceuticals (EIGR) Rating Increased to Strong-Buy at ValuEngineEiger Biopharmaceuticals (EIGR) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 17 at 4:17 PM
Eiger Biopharmaceuticals (EIGR) Given Outperform Rating at WedbushEiger Biopharmaceuticals (EIGR) Given Outperform Rating at Wedbush
www.americanbankingnews.com - May 17 at 3:27 PM
Eiger Biopharmaceuticals (EIGR) Price Target Raised to $39.00 at BTIG ResearchEiger Biopharmaceuticals (EIGR) Price Target Raised to $39.00 at BTIG Research
www.americanbankingnews.com - May 17 at 2:43 PM
Eiger expands license agreement with Merck for Lonafarnib and collaboration with Progeria Research FoundationEiger expands license agreement with Merck for Lonafarnib and collaboration with Progeria Research Foundation
seekingalpha.com - May 16 at 5:42 PM
Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticalsProgeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals
finance.yahoo.com - May 16 at 8:19 AM
Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
finance.yahoo.com - May 16 at 8:19 AM
B. Riley Analysts Increase Earnings Estimates for Eiger Biopharmaceuticals Inc. (EIGR)B. Riley Analysts Increase Earnings Estimates for Eiger Biopharmaceuticals Inc. (EIGR)
www.americanbankingnews.com - May 16 at 7:16 AM
Zacks Investment Research Upgrades Eiger Biopharmaceuticals (EIGR) to BuyZacks Investment Research Upgrades Eiger Biopharmaceuticals (EIGR) to Buy
www.americanbankingnews.com - May 15 at 9:18 PM
Eiger Biopharmaceuticals (EIGR) Releases Quarterly  Earnings Results, Beats Expectations By $0.12 EPSEiger Biopharmaceuticals (EIGR) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - May 12 at 11:15 AM
UPDATE: Eiger BioPharmaceuticals (EIGR) Tops Q1 EPS by 19cUPDATE: Eiger BioPharmaceuticals (EIGR) Tops Q1 EPS by 19c
www.streetinsider.com - May 11 at 5:58 PM
Eiger BioPharma: 1Q Earnings SnapshotEiger BioPharma: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 8:27 AM
Eiger BioPharmaceuticals Reports First Quarter 2018 Financial ResultsEiger BioPharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 11 at 8:27 AM
Q1 2018 Earnings Estimate for Eiger Biopharmaceuticals Inc. Issued By B. Riley (EIGR)Q1 2018 Earnings Estimate for Eiger Biopharmaceuticals Inc. Issued By B. Riley (EIGR)
www.americanbankingnews.com - May 11 at 8:15 AM
Eiger BioPharmaceuticals, Inc. (EIGR)Eiger BioPharmaceuticals, Inc. (EIGR)
finance.yahoo.com - May 10 at 5:57 PM
Eiger Biopharmaceuticals Inc. (EIGR) Given Consensus Recommendation of "Buy" by BrokeragesEiger Biopharmaceuticals Inc. (EIGR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 1:11 PM
Eiger Biopharmaceuticals (EIGR) Coverage Initiated at B. RileyEiger Biopharmaceuticals (EIGR) Coverage Initiated at B. Riley
www.americanbankingnews.com - May 9 at 4:59 PM
 Analysts Expect Eiger Biopharmaceuticals Inc. (EIGR) to Announce -$1.00 Earnings Per Share Analysts Expect Eiger Biopharmaceuticals Inc. (EIGR) to Announce -$1.00 Earnings Per Share
www.americanbankingnews.com - May 3 at 6:10 PM
Eiger Biopharmaceuticals (EIGR) Scheduled to Post Quarterly Earnings on ThursdayEiger Biopharmaceuticals (EIGR) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 1:28 AM
Eiger Biopharmaceuticals (EIGR) Earns "Outperform" Rating from WedbushEiger Biopharmaceuticals (EIGR) Earns "Outperform" Rating from Wedbush
www.americanbankingnews.com - April 26 at 11:19 AM
Eigers lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2%Eiger's lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2%
seekingalpha.com - April 18 at 8:16 AM
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib ...Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib ...
www.prnewswire.com - April 17 at 5:54 PM
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018
finance.yahoo.com - April 17 at 5:54 PM
Zacks: Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Announce -$1.00 EPSZacks: Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Announce -$1.00 EPS
www.americanbankingnews.com - April 16 at 7:11 AM
Eiger Biopharmaceuticals Inc. (EIGR) Given Consensus Rating of "Buy" by BrokeragesEiger Biopharmaceuticals Inc. (EIGR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 15 at 8:19 AM
Eiger Biopharmaceuticals (EIGR) Rating Increased to Buy at ValuEngineEiger Biopharmaceuticals (EIGR) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 13 at 11:10 PM
Eiger Biopharmaceuticals (EIGR) Upgraded to Hold by Zacks Investment ResearchEiger Biopharmaceuticals (EIGR) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 12 at 5:09 PM
Critical Survey: Bavarian Nordic (BVNRY) and Eiger Biopharmaceuticals (EIGR)Critical Survey: Bavarian Nordic (BVNRY) and Eiger Biopharmaceuticals (EIGR)
www.americanbankingnews.com - April 12 at 3:15 PM
Eiger Biopharmaceuticals (EIGR) Given Buy Rating at Piper JaffrayEiger Biopharmaceuticals (EIGR) Given Buy Rating at Piper Jaffray
www.americanbankingnews.com - April 10 at 12:01 PM
Eiger Biopharmaceuticals Inc. (EIGR) Insider Sells $40,000.00 in StockEiger Biopharmaceuticals Inc. (EIGR) Insider Sells $40,000.00 in Stock
www.americanbankingnews.com - April 4 at 11:37 PM
Eiger Biopharmaceuticals (EIGR) Raised to Hold at ValuEngineEiger Biopharmaceuticals (EIGR) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM
Eiger BioPharmaceuticals to Participate in Conferences in AprilEiger BioPharmaceuticals to Participate in Conferences in April
finance.yahoo.com - April 2 at 8:40 AM
Eiger Biopharmaceuticals (EIGR) Raised to "Hold" at ValuEngineEiger Biopharmaceuticals (EIGR) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM
 Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Post -$1.00 Earnings Per Share Brokerages Expect Eiger Biopharmaceuticals Inc. (EIGR) to Post -$1.00 Earnings Per Share
www.americanbankingnews.com - March 30 at 11:30 AM
What Should We Expect From Eiger BioPharmaceuticals Inc’s (NASDAQ:EIGR) Earnings In The Next Couple Of Years?What Should We Expect From Eiger BioPharmaceuticals Inc’s (NASDAQ:EIGR) Earnings In The Next Couple Of Years?
finance.yahoo.com - March 30 at 8:23 AM
Eiger Biopharmaceuticals (EIGR) Given "Overweight" Rating at Piper JaffrayEiger Biopharmaceuticals (EIGR) Given "Overweight" Rating at Piper Jaffray
www.americanbankingnews.com - March 28 at 12:58 PM
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric HypoglycemiaEiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
finance.yahoo.com - March 26 at 8:22 AM
Wedbush Comments on Eiger Biopharmaceuticals Inc.s FY2022 Earnings (EIGR)Wedbush Comments on Eiger Biopharmaceuticals Inc.'s FY2022 Earnings (EIGR)
www.americanbankingnews.com - March 26 at 1:54 AM
Eiger BioPharmaceuticals (EIGR) Reports Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration ProgramEiger BioPharmaceuticals (EIGR) Reports Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
www.streetinsider.com - March 23 at 5:42 PM
Eiger Biopharmaceuticals (EIGR) Upgraded at Zacks Investment ResearchEiger Biopharmaceuticals (EIGR) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 22 at 9:48 PM

SEC Filings

Eiger Biopharmaceuticals (NASDAQ:EIGR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eiger Biopharmaceuticals (NASDAQ:EIGR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eiger Biopharmaceuticals (NASDAQ EIGR) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.